Literature DB >> 27799401

Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.

Marina Tadolini1,2, Rangjung Dolma Lingtsang3,2, Simon Tiberi4,2, Martin Enwerem5,2, Lia D'Ambrosio6,7,2, Tsetan Dorji Sadutshang3, Rosella Centis6, Giovanni Battista Migliori8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27799401     DOI： 10.1183/13993003.01552-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  9 in total

Review 1.  Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

Authors:  Lia D'Ambrosio; Rosella Centis; Simon Tiberi; Marina Tadolini; Margareth Dalcolmo; Adrian Rendon; Susanna Esposito; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

2.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

Review 3.  Newer Drugs for Tuberculosis Prevention and Treatment in Children.

Authors:  Ben J Marais
Journal:  Indian J Pediatr       Date:  2019-02-01       Impact factor: 1.967

4.  Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase.

Authors:  Gregory R Tintinger; Annette J Theron; Helen C Steel; Moloko C Cholo; Jan G Nel; Charles Feldman; Ronald Anderson
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 5.  Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.

Authors:  Yong-Soo Kwon
Journal:  Chonnam Med J       Date:  2017-05-25

Review 6.  Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Authors:  Giovanni Battista Migliori; Emanuele Pontali; Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Simon Tiberi; Marina Tadolini; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2017-02-07       Impact factor: 5.923

7.  Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Authors:  Andrey Maryandyshev; Emanuele Pontali; Simon Tiberi; Onno Akkerman; Shashank Ganatra; Tsetan Dorji Sadutshang; Jan-Willem Alffenaar; Rohit Amale; Jai Mullerpattan; Sonam Topgyal; Zarir Farokh Udwadia; Rosella Centis; Lia D'Ambrosio; Giovanni Sotgiu; Giovanni Battista Migliori
Journal:  Emerg Infect Dis       Date:  2017-10-17       Impact factor: 6.883

8.  WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?

Authors:  Nirmal Kumar Jain
Journal:  Lung India       Date:  2021 Jul-Aug

9.  Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.

Authors:  Erika Mohr; Jennifer Hughes; Anja Reuter; Laura Trivino Duran; Gabriella Ferlazzo; Johnny Daniels; Virginia De Azevedo; Yulene Kock; Sarah Jane Steele; Amir Shroufi; Serge Ade; Natavan Alikhanova; Guido Benedetti; Jeffrey Edwards; Helen Cox; Jennifer Furin; Petros Isaakidis
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.